EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia

Kyaw Hein iD, Nicholas Short, Elias Jabbour, Musa Yilmaz

Blood and Lymphatic Cancer: Targets and Therapy · 2022-03 · Volume 12 · 7-16

DOI: 10.2147/blctt.s270134 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2022-03. Verfasst von Kyaw Hein und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

acute lymphoblastic leukemiaminimal residual diseasemulticolor flow cytometrynext-generation sequencingpolymerase chain reaction

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Kyaw Hein

Zitieren

APA

Hein, K., Short, N., Jabbour, E., & Yilmaz, M. (2022). Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy, Volume 12, 7-16. https://doi.org/10.2147/blctt.s270134

Vancouver

Hein K, Short N, Jabbour E, Yilmaz M. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy. 2022;Volume 12:7-16. doi:10.2147/blctt.s270134

BibTeX
@article{Hein2022,
  author = {Hein, Kyaw and Short, Nicholas and Jabbour, Elias and Yilmaz, Musa},
  title = {Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia},
  journal = {Blood and Lymphatic Cancer: Targets and Therapy},
  year = {2022},
  volume = {Volume 12},
  pages = {7--16},
  doi = {10.2147/blctt.s270134}
}
Kostenlos starten →